Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery, but each of these has its limitations. The company has developed the Hydrus Microstent, the world’s first “intracanalicular scaffold” for the treatment of POAG. The Hydrus procedure is designed to be less invasive than traditional glaucoma surgery and can be performed during cataract surgery using the same microsurgical incisions.

Ivantis has been acquired by Alcon, the global leader in eye care.